Excellent
Aligned
Patient Risk:
Low
Summary
The response’s claims are fully supported by the provided FDA label excerpts: the pediatric/young adult boxed warning, Pediatric Use section (8.4), and Warnings and Precautions (5.1). No contradictions are present.
Category Scores
Accurate Statements
Use of REMERON/REMERONSolTab in pediatric patients with MDD is associated with increased risk of suicidal thoughts and behaviors.
Label text: Warnings and Precautions (5.1) and Pediatric Use (8.4) state antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients.
REMERON/REMERONSolTab is not approved for use in pediatric patients.
Label text: Boxed Warning states REMERON/REMERONSolTab is not approved for use in pediatric patients; Pediatric Use (8.4) states safety/effectiveness have not been established in pediatric patients with MDD.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No unsafe or off-label claims were made; the response only restates on-label boxed warning/pediatric safety statements provided in the label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement